OncBioMune Pharmaceuticals, Inc. Appoints Andrew Kucharchuk as Acting Chief Financial Officer
August 26, 2020 at 04:40 pm EDT
Share
On August 14, 2020, the Board of Directors of OncBioMune Pharmaceuticals, Inc. appointed Mr. Andrew Kucharchuk as Acting Chief Financial Officer of the company, effective immediately. Mr. Kucharchuk is currently a director of the company and served as the company's Chief Financial Officer from 2009 until closing of the acquisition of the assets of Avant Diagnostics, Inc. (Avant) on June 5, 2020.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
THERALINK TECHNOLOGIES, INC. 
